Monthly Archives: March 2016

Weekly Roundup 3.11.16

Posted on March 11, 2016 by Mark Senak

The chives have poked their way up through the winter refuse of leaves and dried stems letting me know it is time to get the garden beds all ready again for Spring and to even be so optimistic as to … Continue reading →

Posted in Weekly Roundup | Comments Off on Weekly Roundup 3.11.16

Socializing Medicine – FDA Enforcement Involving Social Media

Posted on March 9, 2016 by Mark Senak

Have you ever had a conversation with someone who said pharma needs to stay away from social media because it is too risky? Even today, some hold that opinion. When social media, used primarily by individuals in its nascent stage, … Continue reading →

Posted in Social Media, Warning Letters | Comments Off on Socializing Medicine – FDA Enforcement Involving Social Media

Weekly Roundup 3.4.15

Posted on March 4, 2016 by Mark Senak

2016 is speeding by. We are over two-thirds of the way through the first quarter. Mother Nature continues to taunt us. Daffodils were blooming this week, only to have snow accumulating around the blossoms today. Election fever runs rampant as … Continue reading →

Posted in Weekly Roundup | Comments Off on Weekly Roundup 3.4.15

Promotion of Investigational Compound – Historical Overview

Posted on March 3, 2016 by Mark Senak

Communications regarding medicines in development – often referred to as “investigational compounds” can be particularly challenging. On the one hand, there are data milestones and advancements for the product through the regulatory cycle about which there is great interest. On … Continue reading →

Posted in FDA Policy, Regulatory Communications, Warning Letters | Comments Off on Promotion of Investigational Compound – Historical Overview